Cargando…

Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses

Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola v...

Descripción completa

Detalles Bibliográficos
Autores principales: Stonier, Spencer W., Herbert, Andrew S., Kuehne, Ana I., Sobarzo, Ariel, Habibulin, Polina, Dahan, Chen V. Abramovitch, James, Rebekah M., Egesa, Moses, Cose, Stephen, Lutwama, Julius Julian, Lobel, Leslie, Dye, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584125/
https://www.ncbi.nlm.nih.gov/pubmed/28724616
http://dx.doi.org/10.1084/jem.20170161
_version_ 1783261411524214784
author Stonier, Spencer W.
Herbert, Andrew S.
Kuehne, Ana I.
Sobarzo, Ariel
Habibulin, Polina
Dahan, Chen V. Abramovitch
James, Rebekah M.
Egesa, Moses
Cose, Stephen
Lutwama, Julius Julian
Lobel, Leslie
Dye, John M.
author_facet Stonier, Spencer W.
Herbert, Andrew S.
Kuehne, Ana I.
Sobarzo, Ariel
Habibulin, Polina
Dahan, Chen V. Abramovitch
James, Rebekah M.
Egesa, Moses
Cose, Stephen
Lutwama, Julius Julian
Lobel, Leslie
Dye, John M.
author_sort Stonier, Spencer W.
collection PubMed
description Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4(+) T cell responses but limited CD8(+) T cell responses, more in keeping with SUDV survivors than EBOV survivors. In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly after the outbreak. These results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different filoviruses may require different immune responses to achieve immunity.
format Online
Article
Text
id pubmed-5584125
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-55841252018-03-04 Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses Stonier, Spencer W. Herbert, Andrew S. Kuehne, Ana I. Sobarzo, Ariel Habibulin, Polina Dahan, Chen V. Abramovitch James, Rebekah M. Egesa, Moses Cose, Stephen Lutwama, Julius Julian Lobel, Leslie Dye, John M. J Exp Med Research Articles Until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG responses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus immune responses. Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections have provided the most insight, with T cell responses as well as detailed antibody responses having been characterized. Immune responses to Marburg virus (MARV), however, remain almost entirely uncharacterized. We report that immune responses in MARV survivors share characteristics with EBOV and SUDV infections but have some distinct differences. MARV survivors developed multivariate CD4(+) T cell responses but limited CD8(+) T cell responses, more in keeping with SUDV survivors than EBOV survivors. In stark contrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly after the outbreak. These results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different filoviruses may require different immune responses to achieve immunity. The Rockefeller University Press 2017-09-04 /pmc/articles/PMC5584125/ /pubmed/28724616 http://dx.doi.org/10.1084/jem.20170161 Text en © 2017 Stonier et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Research Articles
Stonier, Spencer W.
Herbert, Andrew S.
Kuehne, Ana I.
Sobarzo, Ariel
Habibulin, Polina
Dahan, Chen V. Abramovitch
James, Rebekah M.
Egesa, Moses
Cose, Stephen
Lutwama, Julius Julian
Lobel, Leslie
Dye, John M.
Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
title Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
title_full Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
title_fullStr Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
title_full_unstemmed Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
title_short Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses
title_sort marburg virus survivor immune responses are th1 skewed with limited neutralizing antibody responses
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584125/
https://www.ncbi.nlm.nih.gov/pubmed/28724616
http://dx.doi.org/10.1084/jem.20170161
work_keys_str_mv AT stonierspencerw marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT herbertandrews marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT kuehneanai marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT sobarzoariel marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT habibulinpolina marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT dahanchenvabramovitch marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT jamesrebekahm marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT egesamoses marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT cosestephen marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT lutwamajuliusjulian marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT lobelleslie marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses
AT dyejohnm marburgvirussurvivorimmuneresponsesareth1skewedwithlimitedneutralizingantibodyresponses